Boston scientific initiates randomized controlled trial for the ekosonic™ endovascular system

Marlborough, mass., aug. 4, 2021 /prnewswire/ -- boston scientific corporation (nyse: bsx) has commenced enrollment in the hi-peitho clinical trial, a collaborative research study with the pulmonary embolism response team (pert) consortium and the university medical center of the johannes gutenberg university of mainz comparing use of the ekosonic™ endovascular system (ekos) in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism (pe).
BSX Ratings Summary
BSX Quant Ranking